1–5 of 5 results for Dante Joseph Pieramici
ADVM-022 Intravitreal Gene Therapy for Neovascular AMD: Phase 1 OPTIC Trial Update
Dante Joseph Pieramici, MD
Annual Meeting Talks
2022
Intravitreal Gene Therapy for Neovascular AMD with ADVM-022: Results of the Phase 1 OPTIC Trial
2021
Five-Year Outcomes After Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T)
2020
Updates from the Field
Retinal Nonperfusion and Anti-VEGF Therapy in Diabetic Retinopathy: What We Know and What We Don’t Know
2017